A more-sensitive method to analyze protein interactions has uncovered a new way that cancer cells may use the cell-surface molecule HER3 to drive tumor progression following treatment with HER1 and HER2 inhibitors.
Sep 4, 2012
0
0
Measuring the transfer of tiny amounts of energy from one protein to another on breast cancer cells has given scientists a detailed view of molecular interactions that could help predict how breast cancer patients will respond ...
May 5, 2011
0
0
A new measurement standard developed by the National Institute of Standards of Technology (NIST) has been used successfully by the Frederick National Laboratory for Cancer Research to check the performance of next-generation ...
Aug 17, 2016
0
4
A new study of young women with breast cancer has found that most chose to have a mastectomy rather than a surgical procedure that would conserve the breast, researchers will report at the 49th Annual Meeting of the American ...
May 30, 2013
0
0
A multicenter study led by researchers at UC Davis describes new, paradoxical characteristics of the most common type of breast cancer. The findings shed light on how the disease can evade treatment and could improve diagnosis ...
Dec 14, 2012
0
0
Dublin, Ireland: An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumour activity in a number of cancers including those ...
Nov 14, 2018
0
3
Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical ...
Jul 27, 2016
0
1
New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced ...
Apr 22, 2013
0
0
(HealthDay)—All women with invasive breast cancer should be tested for the HER2 (human epidermal growth factor receptor 2) gene and protein, according to updated guidelines from two expert groups.
Oct 7, 2013
0
0
A drug which targets a key gene fault could halt an aggressive womb cancer and shrink tumours, according to research published in the British Journal of Cancer.
Sep 30, 2014
0
0
